KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Invested Capital (2016 - 2025)

Historic Invested Capital for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $67.3 billion.

  • Bristol Myers Squibb's Invested Capital rose 85.4% to $67.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $67.3 billion, marking a year-over-year increase of 85.4%. This contributed to the annual value of $65.8 billion for FY2024, which is 462.53% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Invested Capital stood at $67.3 billion for Q3 2025, which was up 85.4% from $66.4 billion recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's Invested Capital peaked at $88.7 billion during Q4 2021, and registered a low of $65.8 billion during Q4 2024.
  • For the 5-year period, Bristol Myers Squibb's Invested Capital averaged around $73.0 billion, with its median value being $69.1 billion (2023).
  • As far as peak fluctuations go, Bristol Myers Squibb's Invested Capital plummeted by 1795.93% in 2023, and later skyrocketed by 102.16% in 2024.
  • Bristol Myers Squibb's Invested Capital (Quarter) stood at $88.7 billion in 2021, then decreased by 5.2% to $84.1 billion in 2022, then fell by 17.96% to $69.0 billion in 2023, then decreased by 4.63% to $65.8 billion in 2024, then grew by 2.28% to $67.3 billion in 2025.
  • Its Invested Capital stands at $67.3 billion for Q3 2025, versus $66.4 billion for Q2 2025 and $67.0 billion for Q1 2025.